The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Inflammatory cortical demyelination in early multiple sclerosis.
Open accessAbstract
BACKGROUND: Cortical disease has emerged as a critical aspect of the pathogenesis of multiple sclerosis, being associated with disease progression and cognitive impairment. Most studies of cortical lesions have focused on autopsy findings in patients with long-standing, chronic, progressive multiple sclerosis, and the noninflammatory nature of these lesions has been emphasized. Magnetic resonance imaging studies indicate that cortical damage occurs early in the disease. METHODS: We evaluated the prevalence and character of demyelinating cortical lesions in patients with multiple sclerosis. Cortical tissues were obtained in passing during biopsy sampling of white-matter lesions. In most cases, biopsy was done with the use of stereotactic procedures to diagnose suspected tumors. Patients with sufficient cortex (138 of 563 patients screened) were evaluated for cortical demyelination. Using immunohistochemistry, we characterized cortical lesions with respect to demyelinating activity, inflammatory infiltrates, the presence of meningeal inflammation, and a topographic association between cortical demyelination and meningeal inflammation. Diagnoses were ascertained in a subgroup of 77 patients (56%) at the last follow-up visit (at a median of 3.5 years). RESULTS: Cortical demyelination was present in 53 patients (38%) (104 lesions and 222 tissue blocks) and was absent in 85 patients (121 tissue blocks). Twenty-five patients with cortical demyelination had definite multiple sclerosis (81% of 31 patients who underwent long-term follow-up), as did 33 patients without cortical demyelination (72% of 46 patients who underwent long-term follow-up). In representative tissues, 58 of 71 lesions (82%) showed CD3+ T-cell infiltrates, and 32 of 78 lesions (41%) showed macrophage-associated demyelination. Meningeal inflammation was topographically associated with cortical demyelination in patients who had sufficient meningeal tissue for study. CONCLUSIONS: In this cohort of patients with early-stage multiple sclerosis, cortical demyelinating lesions were frequent, inflammatory, and strongly associated with meningeal inflammation. (Funded by the National Multiple Sclerosis Society and the National Institutes of Health.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This may well reflect the greater microglia and astrocyte activity in the white matter; pure cortical lesions in post-mortem tissues show little or no inflammation (Bo et al., 2004; Brink et al., 2005; van Horssen et al., 2007), although early lesions have been associated with prominent microglial activation (Lucchinetti et al., 2011).”
From A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis (2019) · cites this paper as Lucchinetti et al., 2011
In the citing paper
“Biopsies taken from early MS patients with cortical demyelination were more likely to have leptomeningeal inflammation, consisting of effector T cells and IgA B cells infiltrates, than those without cortical demyelination.”
From Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease (2021) · cites this paper as Lucchinetti et al., 2011
In the citing paper
“The leptomeninges are now recognized as a key player in multiple sclerosis (MS), an inflammatory CNS autoimmune disorder characterized by axon demyelination”
From Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease (2021) · cites this paper as Lucchinetti et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Revised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,568
Self-citationCortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Self-citationMagliozzi, R., Howell, O. W., Vora, A., Serafini, B., Nicholas, R. S., Puopolo, M., Reynolds, R., & Aloisi, F. (2006) · Brain · doi:10.1093/brain/awm038 · Cited by 1,486
Peterson, J. W., Bö, L., Mörk, S., Chang, A., & Trapp, B. D. (2001) · Annals of Neurology · doi:10.1002/ana.1123 · Cited by 1,403
Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E., & Aloisi, F. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00049.x · Cited by 1,208
Reboldi, A., Coisne, C., Baumjohann, D., Benvenuto, F., Bottinelli, D., Lira, S., Uccelli, A., Lanzavecchia, A., Engelhardt, B., & Sallusto, F. (2009) · Nature Immunology · doi:10.1038/ni.1716 · Cited by 1,206
Cortical lesions in multiple sclerosis
Kidd, D., Barkhof, F., McConnell, R., Algra, P. R., Allen, I. V., & Revesz, T. (1999) · Brain · doi:10.1093/brain/122.1.17 · Cited by 766
Subpial Demyelination in the Cerebral Cortex of Multiple Sclerosis Patients
Bø, L., Vedeler, C. A., Nyland, H. I., Trapp, B. D., & Mørk, S. J. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.7.723 · Cited by 757
Flagged first, then by citations
Research works printed but not linked: 1
- Tardif CL, 2010, Med Image Comput Assist Interv, 13, 181
Cited by
Sorted by citations
Items 801–900 of 1,000
The role of sleep in multiple sclerosis
Cordone, S., Alfonsi, V., & Gennaro, L. D. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103902 · Cited by 5
Do not treat from CIS onset: evaluate disease course and prognosis first - No (treat!)
Freedman, M. S. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512440605 · Cited by 5
Dutta, R. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513500554 · Cited by 5
Hollingsworth, E. W., Khouri, J., & Imitola, J. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1287564 · Cited by 5
Decision trees to evaluate the risk of developing multiple sclerosis
Pasella, M., Pisano, F., Cannas, B., Fanni, A., Cocco, E. E., Frau, J., Lai, F., Mocci, S., Littera, R., & Giglio, S. (2023) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2023.1248632 · Cited by 5
Xue, H., Arbini, A., Melton, H. J., & Kister, I. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.105047 · Cited by 5
Calabrese, M., Gajofatto, A., & Benedetti, M. D. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.979794 · Cited by 5
Alifirova, V. M., Kamenskikh, E. M., & Koroleva, E. S. (2019) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2019119107 · Cited by 5
Okar, S. V., & Reich, D. S. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.21.26999 · Cited by 5
Pathology of Multiple Sclerosis
Dunham, J., & Mahajan, K. R. (2021) · Springer eBooks · doi:10.1007/978-3-030-61883-4_8 · Cited by 6
Molecular mechanisms associated with multiple sclerosis progression, severity and phenotypePreprint
Kosa, P. F., Lumbard, K., Wang, J., Liang, C., Masvekar, R., Kim, Y., Varosanec, M., Jennings, L. L., & Bielekova, B. (2022) · medRxiv · doi:10.1101/2022.10.14.22281095 · Cited by 5
Guo, Y., Dong, D., Wu, H., Xue, Z., Zhou, F., Zhao, L., Li, Z., & Feng, T. (2023) · Cerebral Cortex · doi:10.1093/cercor/bhad028 · Cited by 5
Cooze, B., Neal, J., Vineed, A., Oliveira, J. C., Griffiths, L., Allen, K. H., Hawkins, K., Yadanar, H., Gerhards, K., Farkas, I., et al. (2024) · Cells · doi:10.3390/cells13121020 · Cited by 5
Krijnen, E. A., Kouwenhoven, R.-M., Noteboom, S., Barkhof, F., Uitdehaag, B. M. J., Klawiter, E. C., Steenwijk, M. D., Schoonheim, M. M., & Koubiyr, I. (2024) · Multiple Sclerosis Journal · doi:10.1177/13524585241260968 · Cited by 4
Zurawski, J. D., Tauhid, S., Healy, B. C., Chu, R., Houtchens, M. K., Jalkh, Y., Khalil, S., Quattrucci, M., Mateen, F. J., Napoli, S. Q., et al. (2025) · Journal of Neuroimaging · doi:10.1111/jon.70032 · Cited by 4
Talukdar, G., Duvick, L. A., Yang, P., O’Callaghan, B. L., Fuchs, G. J., Cvetanović, M., & Orr, H. T. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03450-2 · Cited by 4
Etemadifar, M., Rezaei, K., Hojjatipour, F., & Salari, M. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106569 · Cited by 4
Florescu, A., Zuo, M., Wang, A. A., Champagne-Jorgensen, K., Noor, M. A., Ward, L. A., van Puijenbroek, E., Klein, C., & Gommerman, J. L. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241255 · Cited by 6
Damulina, A., Opriessnig, P., Pirpamer, L., Demjaha, R., Tafrali, C., Martinez-Serrat, M., Hofer, E., Wurth, S., Heschl, B., Hochmeister, S., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000214433 · Cited by 4
Therapeutics of Integrative Medicine Ameliorate Immunological Disorders of the Nervous System
Cheng, X.-D., Ma, J., Cruz, J., Jin, J., Peng, X.-Y., & Ai-Ming, Z. (2022) · World Journal of Traditional Chinese Medicine · doi:10.4103/2311-8571.336837 · Cited by 4
Enz, L., Winkler, A., Wrzos, C., Dasen, B., Nessler, S., Stadelmann, C., & Schaeren‐Wiemers, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813893 · Cited by 4
Marchi, L., Mariottini, A., Viti, V., Bianchi, A., Nozzoli, C., Repice, A. M., Boncompagni, R., Ginestroni, A., Damato, V., Barilaro, A., et al. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1373385 · Cited by 5
Infrared spectral profiling of demyelinating activity in multiple sclerosis brain tissue
Gakh, O., Wilkins, J. M., Guo, Y., Popescu, B. F., Weigand, S. D., Kalinowska-Lyszczarz, A., & Lucchinetti, C. F. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01854-4 · Cited by 4
Self-citationTertiary Lymphoid Structures in Central Nervous System Disorders
Vaccaro, A., Pereira, B. D. A., van de Walle, T., & Dimberg, A. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-4184-2_2 · Cited by 4
Miclea, A., Zurawski, J. D., Healy, B. C., Saxena, S., Lokhande, H. A., Quattrucci, M., Chu, R., Weiner, H. L., Bakshi, R., & Chitnis, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-95229-x · Cited by 4
Nefodov, A., Belenichev, I. F., Nefodova, E., Bukhtiyarova, N. V., Левич, С. В., & Dronov, S. (2018) · The Journal of Neurobehavioral Sciences · doi:10.5455/jnbs.1525619232 · Cited by 4
Naseri, M., Rezaeizadeh, H., Mirghazanfari, S. M., Taheripanah, T., Bararpoor, Z., Ashayeri, N., Asghari, M., Shahi, A. T. M., Emadi, F., Moghaddam, P. M., et al. (2021) · European Journal of Translational Myology · doi:10.4081/ejtm.2022.10169 · Cited by 4
Trufanov, A. G., Бисага, Г. Н., Скулябин, Д. И., Тёмный, А. В., Юрин, А. А., Попляк, М. О., Полтавский, И. Д., Литвиненко, И. В., Одинак, М. М., & Тарумов, Д. А. (2020) · Annals of Clinical and Experimental Neurology · doi:10.25692/acen.2020.3.3 · Cited by 4
Cell‐based experimental strategies for myelin repair in multiple sclerosis
Borda, M., Aquino, J. B., & Mazzone, G. L. (2022) · Journal of Neuroscience Research · doi:10.1002/jnr.25129 · Cited by 4
IgM to phosphatidylcholine in multiple sclerosis patients: from the diagnosis to the treatment
Sánchez‐Vera, I., Escudero, E., Muñoz, Ú., & Sádaba, M. C. (2023) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864231189919 · Cited by 5
Alassiri, M., Sufiani, F. A., Aljohi, M., Alanazi, A., Alhazmi, A. S., Alrfaei, B. M., Alnakhli, H., Alshawakir, Y. A., Alharby, S. M., Almubarak, A. Y., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417243 · Cited by 4
Satoh, J., & Kino, Y. (2015) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12218 · Cited by 4
Organes lymphoïdes tertiaires méningés : des acteurs majeurs de l’auto-immunité intrathécale
Bonnan, M. (2014) · Revue Neurologique · doi:10.1016/j.neurol.2014.08.003 · Cited by 5
Molecular targeted therapy against B cells in multiple sclerosis
Miyazaki, Y., & Niino, M. (2014) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12160 · Cited by 4
The Pathophysiology and Clinical Presentation of Multiple Sclerosis
Horng, S. H., & Fabian, M. T. (2017) · Springer eBooks · doi:10.1007/978-3-319-40628-2_2 · Cited by 4
Daclizumab for the Treatment of Multiple Sclerosis
Papadopoulou, A., Derfuss, T. J., & Sprenger, T. (2017) · Neurodegenerative Disease Management · doi:10.2217/nmt-2017-0023 · Cited by 4
Unraveling the T–B tangle in anti-CD20 multiple sclerosis therapy
Waisman, A., & Ebering, A. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919044116 · Cited by 4
B cells in autoimmune diseases of the central nervous system
Noto, D., & Miyake, S. (2020) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12603 · Cited by 4
Droby, A., Fleysher, L., Petracca, M., Podranski, K., Xu, J., Fabian, M. T., Marjańska, M., & Inglese, M. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102183 · Cited by 4
Toko, M., Kitamura, J., Ueno, H., Ohshita, T., Nemoto, K., Ochi, K., Higaki, T., Akiyama, Y., Awai, K., & Maruyama, H. (2020) · Internal Medicine · doi:10.2169/internalmedicine.5058-20 · Cited by 4
Role of B cells in the pathogenesis of multiple sclerosis
Ochi, H. (2021) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12671 · Cited by 4
VLA-4 as a Central Target for Modulating Neuroinflammatory Disorders
Jurberg, A. D., Chaves, B., Pinho, L. G., da Silva, J. H. M., Savino, W., & Cotta-de-Almeida, V. (2021) · NeuroImmunoModulation · doi:10.1159/000518721 · Cited by 4
Chihara, N., Tsuji, A., & Matsumoto, R. (2023) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12747 · Cited by 4
The Neuropathology of Progressive Multiple Sclerosis
Bø, L., Evangelou, N., & Tallantyre, E. C. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2395-8_4 · Cited by 4
New Concepts Related to Disease Appreciation in Multiple Sclerosis
Azevedo, C. J., Jaberzadeh, A., & Pelletier, D. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.08.010 · Cited by 4
Cortical Lesions in Multiple Sclerosis
Naismith, R. T. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1422 · Cited by 4
Inflammation in Multiple Sclerosis — Sorting Out the Gray Matter
Calabresi, P. A. (2011) · New England Journal of Medicine · doi:10.1056/nejme1111945 · Cited by 4
Matías‐Guiu, J. A., Cabrera‐Martín, M. N., Pytel, V., Montero, P., Carreras, J. L., & Matías‐Guiu, J. (2020) · Annals of Neurology · doi:10.1002/ana.25759 · Cited by 4
Not everything that can be counted counts, and not everything that counts can be counted.
Lien, F. R. (2014) · NORA - Norwegian Open Research Archives · Cited by 4
WITHDRAWN: Border-associated macrophages in the central nervous system
Sun, R., & Jiang, H. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.109921 · Cited by 4
RetractedImaging Outcomes for Phase 2 Trials Targeting Compartmentalized Inflammation
Gaitán, M. I., Márquez, R., Ayerbe, J., & Reich, D. S. (2024) · Multiple Sclerosis Journal · doi:10.1177/13524585241301303 · Cited by 3
Detection of cognitive deficits years prior to clinical diagnosis across neurological conditions
Tai, X. Y., Toniolo, S., Llewellyn, D. J., van Duijn, C. M., Husain, M., & Manohar, S. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf307 · Cited by 3
Shin, J., Götz, P., Sharif, N., Sola-Sevilla, N., Grasmuck, C., Schraad, M., Pape, K., Muthuraman, M., Fleischer, V., Zandee, S., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adx2652 · Cited by 3
Kosa, P. F., Ashida, S., Lumbard, K., Wang, J., Liang, C., Masvekar, R., Kim, Y., Varosanec, M., Jennings, L. L., & Bielekova, B. (2025) · Nature Communications · doi:10.1038/s41467-025-65154-8 · Cited by 3
Germundson-Hermanson, D., Klug, M. G., & Nagamoto‐Combs, K. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10256-9 · Cited by 3
Therapeutic potential of TAM receptors in autoimmune diseases: insights from original studies
Adedayo, S. I., Gegele, T. A., Adeshina, K. A., Olukade, B. A., Abubakar, R. A., Abdulsalam, A., Oladejo, T. O., Ahmed, M. M., & Ibrahim, K. G. (2026) · Oxford Open Immunology · doi:10.1093/oxfimm/iqag001 · Cited by 3
Bufi, A. A., Papait, A., Ponsaerts, P., Silini, A. R., & Parolini, O. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00554-4 · Cited by 3
Gray matter involvement in multiple sclerosis and neuromyelitis optica
Kawachi, I., & Nishizawa, M. (2014) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12077 · Cited by 3
Role of Neuroimaging in Multiple Sclerosis
Zivadinov, R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800763-1.00018-x · Cited by 3
Ofatumumab – A Potential Subcutaneous B-cell Therapy for Relapsing Multiple Sclerosis
Milo, R. (2020) · European Neurological Review · doi:10.17925/enr.2020.15.1.27 · Cited by 3
Kurniawan, N. D. (2021) · Open Access Journal of Biomedical Science · doi:10.38125/oajbs.000263 · Cited by 3
Experimental laboratory biomarkers in multiple sclerosis
Arneth, B. M., & Kraus, J. (2022) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-022-00920-7 · Cited by 3
Multiple sclerosis and related disorders: where do we stand in 2022?
Kalinowska, A. (2022) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.2022.0048 · Cited by 3
Brain Morphometry in Multiple Sclerosis
Lipp, I., Muhlert, N., & Tomassini, V. (2018) · Neuromethods · doi:10.1007/978-1-4939-7647-8_17 · Cited by 3
Neuropathological features of “non‐motor” symptoms in multiple sclerosis and neuromyelitis optica
Kawachi, I. (2019) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12533 · Cited by 3
Nanoengineering and nanotechnology for diagnosis and treatment of CNS and neurological diseases
Kumar, P., Dwivedi, A., Plaimas, K., Sagar, K., & Chauhan, L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91182-5.00006-1 · Cited by 3
Frid, K., Usman, A., Markovits-Pachter, T., Binyamin, O., Petrou, P., Kassis, I., Karussis, D., & Gabizon, R. (2024) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2024.578313 · Cited by 3
Georgieva, T., Diddens, J., Friedrich, V., Lepennetier, G., Brand, R. M., & Lehmann‐Horn, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1400641 · Cited by 3
Simka, M. (2013) · Journal of Neuroparasitology · doi:10.4303/jnd/235688 · Cited by 3
Intrathecal Immunoglobulin Synthesis in MS—A Complete Reappraisal
Bonnan, M. (2016) · InTech eBooks · doi:10.5772/63201 · Cited by 3
Alatrash, R., Golubenko, M., Martynova, E. V., Garanina, E. E., Mukhamedshina, Y. O., Khaiboullina, S. F., Rizvanov, A. A., Salafutdinov, I. I., & Arkhipova, S. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098332 · Cited by 4
Mausner-Fainberg, K., Kolb, H., Penn, M., Regev, K., Vaknin‐Dembinsky, A., Gadoth, A., Kestenbaum, M., & Karni, A. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.01.019 · Cited by 3
Bettcher, B. M., Bevan, C. J., & Geschwind, M. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800105-9.00041-x · Cited by 3
Robust cell detection of histopathological brain tumor images and analyzing its textual features
Khan, S., & Surya, S. R. (2017) · International Conference on Communication and Electronics Systems (ICCES) · doi:10.1109/cesys.2017.8321210 · Cited by 3
Ofatumumab — a new drug for the treatment of multiple sclerosis
Boyko, A. N., Смирнова, Н. Ф., Щукин, И. А., Guseva, M. E., & Volkov, A. I. (2021) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202112107237 · Cited by 3
Can PET imaging tell us what's the matter with the gray matter in multiple sclerosis?
Calabresi, P. A., & Bohnen, N. I. (2012) · Neurology · doi:10.1212/wnl.0b013e3182635824 · Cited by 3
Karussis, D. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803678-5.00295-2 · Cited by 6
Margins of control: ventricular brain borders as architects in central nervous system autoimmunity
Premachandran, S., Groh, A. M. R., Sinott, A., Senthil, S., Rudko, D. A., Narayanan, S., Moore, G. R. W., & Stratton, J. A. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag023 · Cited by 2
Therapeutic ultrasound for the treatment of demyelinating diseases
Micali, M., Toschi, N., & Conti, A. (2026) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2026.102913 · Cited by 2
Magnetic Resonance Imaging of Neuroinflammation
Johanssen, V. A., Zarghami, N., & Sibson, N. R. (2023) · Progress in inflammation research · doi:10.1007/978-3-031-23661-7_3 · Cited by 3
Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
Yavari, F., Oliazadeh, P., Radfar, M., Foroughipour, M., Nikkhah, K., Bakavoli, A. H., & Saeidi, M. (2021) · Basic and Clinical Neuroscience Journal · doi:10.32598/bcn.12.2.1681.1 · Cited by 2
Síndrome acento extranjero en Esclerosis Múltiple, revisión y presentación de un caso.
Barriga-Maldonado, V., Posadas-Pinto, D. R., Cruz-Guillermo, M., López-Hernández, D. C., & Frenk, I. T. (2021) · Archivos de Neurociencias · doi:10.31157/an.v26i3.225 · Cited by 3
Sahakyan, A., & Mavelyan, H. M. (2022) · Neurology India · doi:10.4103/0028-3886.349619 · Cited by 2
Quantitative T1ρ MR Imaging in Neuroradiology
Filippi, C. G., Klebba, A., Hipko, S. G., & Watts, R. (2023) · Springer eBooks · doi:10.1007/978-3-031-10909-6_56 · Cited by 2
Th17-Mediated Immune Responses in Pathogenesis of Neuroinflammatory Disorders
Pourgholaminejad, A., & Tahmasebinia, F. (2024) · Springer eBooks · doi:10.1007/978-3-031-60006-7_3 · Cited by 2
Cortical Pathology in RRMS: Taking a Cue from Four Sisters
Calabrese, M., Seppi, D., Cocco, E. E., Poretto, V., Rinaldi, F., Perini, P., & Gallo, P. (2012) · Multiple Sclerosis International · doi:10.1155/2012/760254 · Cited by 2
Current and Future Treatments of Multiple Sclerosis
Haghikia, A., & Gold, R. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7953-6_17 · Cited by 2
B‐cell‐targeted therapy in multiple sclerosis
Ochi, H. (2016) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12328 · Cited by 2
Acute, Chronic, and Nonclassical Neuroinflammation: Definitions in a Changing Scientific Environment
Lisak, R. P., & Benjamins, J. A. (2013) · Advances in neurobiology · doi:10.1007/978-1-4614-8313-7_1 · Cited by 2
The Neuropathology of Progressive Multiple Sclerosis
Evangelou, N., Paine, S., & Tallantyre, E. C. (2017) · Springer eBooks · doi:10.1007/978-3-319-65921-3_3 · Cited by 2
(2014) · International Journal of MS Care · doi:10.7224/1537-2073-16.s6.1 · Cited by 2
Barbado, D., Gómez-Illán, R., Moreno, P., Láiz, N. M., Vaíllo, R. R., & Sempere, Á. P. (2018) · Deposito Digital UFV (Francisco de Vitoria University) · Cited by 2
Mosavi-Mehr, M., & Mesbah‐Namin, S. A. (2020) · Archives of Neuroscience · doi:10.5812/ans.104209 · Cited by 2
An Overview and Management of Multiple Chronic Conditions
Akarsu, S. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.83051 · Cited by 2
New concepts on immunology of Multiple Sclerosis
Couloume, L., & Michel, L. (2021) · La Presse Médicale · doi:10.1016/j.lpm.2021.104072 · Cited by 2
Multiple Sclerosis and Acute Disseminated Encephalomyelitis: Immunology
Bailey, M., Hafler, D. A., & Pelletier, D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-385157-4.00186-x · Cited by 2
Epigenetics of autoimmune diseases
Farhadi, E., & Mahmoudi, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814259-2.00009-1 · Cited by 1
Wang, Q., Shen, L., Guo, M., Wang, B., Liu, H., Xiao, K., Shi, Z.-C., & Ji, W. (2025) · Aquaculture · doi:10.1016/j.aquaculture.2025.742179 · Cited by 1
Frank, C., Allen, K. J. H., Dawicki, W., Levin, M. C., & Dadachova, E. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1593933 · Cited by 1
Polysialic acid restrains inflammatory monocyte maturation
Passos, I. B. S., Peschke, B., Gandhi, S., Derdelinckx, J., Müller‐Miny, L., Neumann, H., Lünemann, J. D., & Keller, C. W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1656087 · Cited by 1
Metadata
- Authors
- Lucchinetti, C. F., Popescu, B. F. G., Bunyan, R. F., Moll, N. M., Roemer, S. F., Lassmann, H., Brück, W., Parisi, J. E., Scheithauer, B. W., Giannini, C., Weigand, S. D., Mandrekar, J., & Ransohoff, R. M.
- Affiliations
- Mayo Clinic (US)
- Cleveland Clinic Research (US)
- Medical University of Vienna (AT)
- Universitätsmedizin Göttingen (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-12-08
- Volume
- 365
- Issue
- 23
- Pages
- 2188-2197
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3282172
- OpenAlex
- W2113948549
- Cited by
- 1,103
- References
- 50
- Citations by year
- 2026: 37 · 2025: 44 · 2024: 69 · 2023: 70 · 2022: 68 · 2021: 104 · 2020: 75 · 2019: 83 · 2018: 64 · 2017: 72 · 2016: 75 · 2015: 84 · 2014: 89 · 2013: 100 · 2012: 67
- FWCI
- 58.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- National Multiple Sclerosis Society (RG3185-B-3)
- Multiple Sclerosis Society
- National Institutes of Health (P50NS38667)
- National Institute of Neurological Disorders and Stroke (P50NS38667, P50NS038667, R01NS049577)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- multiple sclerosis, cortical demyelination, inflammatory demyelination, meningeal inflammation, cortical lesions, early multiple sclerosis, white matter lesions, stereotactic biopsy, disease progression
- MeSH terms
- Biopsy, Cerebral Cortex, Humans, Inflammation, Multiple Sclerosis, Prevalence, Logistic Models, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
